Free Trial
→ Uranium Mine Flood That Sparked a 2006 Price Surge Returns (From Digest Publishing) (Ad)tc pixel Free ALXO Stock Alerts

ALX Oncology (ALXO) Financials

ALX Oncology logo
$1.00 -0.08 (-7.41%)
As of 11:42 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for ALX Oncology

Annual Income Statements for ALX Oncology

This table shows ALX Oncology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -17 -23 -51 0.00 0.00 -161 -135 -102
Consolidated Net Income / (Loss)		 -14 -19 -46 -83 -123 -161 -135 -102
Net Income / (Loss) Continuing Operations		 -14 -19 -46 -83 -123 -161 -135 -102
Total Pre-Tax Income 		-14 -19 -45 -83 -123 -161 -135 -102
Total Operating Income		 -14 -19 -44 -84 -127 -170 -142 -104
Total Gross Profit		 2.07 4.80 1.18 0.00 0.00 0.00 0.00 0.00
Total Revenue		 2.07 4.80 1.18 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 16 24 45 84 127 170 142 104
Selling, General & Admin Expense		 2.60 3.31 15 23 29 28 26 24
Research & Development Expense		 11 16 29 60 98 142 116 77
Impairment Charge		 - - - - - 0.00 0.00 3.18
Total Other Income / (Expense), net		 -0.00 -0.03 -1.84 0.07 4.02 9.47 7.62 2.33
Interest Expense		 0.00 0.00 0.62 0.01 0.24 1.57 1.73 1.60
Interest & Investment Income		 0.00 -0.02 0.12 0.09 4.28 11 9.37 3.96
Other Income / (Expense), net		 -0.00 -0.01 -1.34 -0.01 -0.02 0.39 -0.02 -0.04
Income Tax Expense		 0.05 0.03 0.24 -0.02 0.06 0.00 0.00 0.00
Basic Earnings per Share		 ($6.33) ($7.56) - ($2.07) ($3.03) ($3.74) ($2.58) ($1.90)
Weighted Average Basic Shares Outstanding		 2.75M 3.08M 18.49M 40.31M 40.70M 42.99M 52.17M 53.66M
Diluted Earnings per Share		 ($6.33) ($7.56) - ($2.07) ($3.03) ($3.74) ($2.58) ($1.90)
Weighted Average Diluted Shares Outstanding		 2.75M 3.08M 18.49M 40.31M 40.70M 42.99M 52.17M 53.66M
Weighted Average Basic & Diluted Shares Outstanding		 2.75M 3.08M 18.49M 40.31M 40.86M 50.15M 53.38M 131.61M

Quarterly Income Statements for ALX Oncology

This table shows ALX Oncology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -45 -36 -39 -31 106 -31 -26 -22 -23 -18 -18
Consolidated Net Income / (Loss)		 -45 -36 -39 -31 -29 -31 -26 -22 -23 -18 -18
Net Income / (Loss) Continuing Operations		 -45 -36 -39 -31 -29 -31 -26 -22 -23 -18 -18
Total Pre-Tax Income 		-45 -36 -39 -31 -29 -31 -26 -22 -23 -18 -18
Total Operating Income		 -48 -38 -42 -33 -31 -32 -27 -23 -23 -19 -18
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 48 38 42 33 31 32 27 23 23 19 18
Selling, General & Admin Expense		 6.24 6.05 6.87 6.10 7.08 7.93 5.45 5.09 5.38 5.36 5.13
Research & Development Expense		 42 32 35 26 24 24 18 17 18 14 13
Other Special Charges / (Income)		 - - - - - - 3.18 - - - -0.24
Total Other Income / (Expense), net		 2.55 2.18 2.13 1.86 1.45 1.07 0.70 0.39 0.17 1.04 0.06
Interest Expense		 0.42 0.43 0.43 0.45 0.43 0.41 0.41 0.41 0.38 0.33 1.19
Interest & Investment Income		 3.00 2.62 2.56 2.30 1.88 1.48 1.11 0.80 0.57 1.18 1.51
Other Income / (Expense), net		 -0.03 -0.01 -0.01 0.00 -0.00 -0.01 -0.00 -0.01 -0.02 0.19 -0.26
Basic Earnings per Share		 ($0.92) ($0.71) ($0.76) ($0.58) ($0.53) ($0.58) ($0.49) ($0.41) ($0.42) ($0.17) ($0.13)
Weighted Average Basic Shares Outstanding		 42.99M 50.12M 51.83M 52.69M 52.17M 53.36M 53.45M 53.58M 53.66M 104.57M 135.64M
Diluted Earnings per Share		 ($0.92) ($0.71) ($0.76) ($0.58) ($0.53) ($0.58) ($0.49) ($0.41) ($0.42) ($0.17) ($0.13)
Weighted Average Diluted Shares Outstanding		 42.99M 50.12M 51.83M 52.69M 52.17M 53.36M 53.45M 53.58M 53.66M 104.57M 135.64M
Weighted Average Basic & Diluted Shares Outstanding		 50.15M 52.10M 52.67M 52.74M 53.38M 53.44M 53.55M 54.22M 131.61M 134.56M 138.28M

Annual Cash Flow Statements for ALX Oncology

This table details how cash moves in and out of ALX Oncology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -14 0.76 425 -71 -315 -26 -4.84 -1.19
Net Cash From Operating Activities		 -13 -14 -38 -68 -89 -130 -122 -84
Net Cash From Continuing Operating Activities		 -13 -14 -38 -68 -89 -130 -122 -84
Net Income / (Loss) Continuing Operations		 -14 -19 -46 -83 -123 -161 -135 -102
Consolidated Net Income / (Loss)		 -14 -19 -46 -83 -123 -161 -135 -102
Depreciation Expense		 0.43 0.43 0.20 0.05 0.34 0.84 0.87 0.71
Amortization Expense		 0.00 0.01 0.42 0.00 -0.90 -6.24 -4.39 -0.96
Non-Cash Adjustments To Reconcile Net Income		 0.27 0.30 6.58 19 25 28 29 17
Changes in Operating Assets and Liabilities, net		 -0.16 4.25 0.25 -4.03 9.85 8.30 -12 0.34
Net Cash From Investing Activities		 -0.65 -0.35 0.61 -4.92 -235 45 86 83
Net Cash From Continuing Investing Activities		 -0.65 -0.35 0.61 -4.92 -235 45 86 83
Purchase of Property, Plant & Equipment		 -0.65 -0.35 -0.03 -0.67 -1.43 -1.27 -0.45 -0.21
Purchase of Investments		 - - 0.00 0.00 -377 -247 -107 -52
Sale and/or Maturity of Investments		 - - 0.00 0.00 143 293 194 134
Net Cash From Financing Activities		 0.00 15 463 2.47 9.86 59 31 0.36
Net Cash From Continuing Financing Activities		 0.00 15 463 2.47 9.86 59 31 0.36
Repayment of Debt		 0.00 0.00 -6.51 0.00 -0.66 0.00 0.00 -0.44
Issuance of Common Equity		 0.00 0.00 368 0.20 0.34 59 30 1.71
Other Financing Activities, net		 0.01 0.01 0.30 2.27 0.18 -0.12 0.81 -0.92
Cash Interest Paid		 0.00 0.00 0.43 0.01 0.10 1.18 1.39 1.26
Cash Income Taxes Paid		 0.00 0.00 0.05 0.27 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for ALX Oncology

This table details how cash moves in and out of ALX Oncology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 2.82 -8.37 1.49 0.57 1.47 3.05 -1.31 4.14 -7.07 16 -9.40
Net Cash From Operating Activities		 -40 -38 -27 -25 -32 -25 -23 -17 -19 -19 -16
Net Cash From Continuing Operating Activities		 -40 -38 -27 -25 -32 -25 -23 -17 -19 -19 -16
Net Income / (Loss) Continuing Operations		 -45 -36 -39 -31 -29 -31 -26 -22 -23 -18 -18
Consolidated Net Income / (Loss)		 -45 -36 -39 -31 -29 -31 -26 -22 -23 -18 -18
Depreciation Expense		 0.21 0.21 0.22 0.22 0.21 0.21 0.19 0.15 0.15 0.15 0.09
Amortization Expense		 -1.82 -1.49 -1.25 -0.98 -0.67 -0.46 -0.24 -0.15 -0.11 -0.13 -0.28
Non-Cash Adjustments To Reconcile Net Income		 7.07 7.49 7.65 7.41 6.33 5.69 5.77 2.92 3.09 2.90 1.59
Changes in Operating Assets and Liabilities, net		 0.33 -8.56 6.21 -1.32 -8.76 0.65 -3.17 2.12 0.74 -3.64 0.51
Net Cash From Investing Activities		 -17 26 0.91 26 33 28 22 21 11 -105 6.52
Net Cash From Continuing Investing Activities		 -17 26 0.91 26 33 28 22 21 11 -105 6.52
Purchase of Property, Plant & Equipment		 -0.15 -0.15 -0.09 -0.15 -0.06 -0.06 -0.05 -0.06 -0.05 -0.05 -0.02
Purchase of Investments		 -75 -31 -63 -8.71 -4.44 -16 -25 -4.44 -5.97 -124 -5.75
Sale and/or Maturity of Investments		 58 58 64 35 38 43 48 26 17 20 12
Net Cash From Financing Activities		 59 3.09 27 0.25 0.33 0.07 -0.22 -0.16 0.68 140 0.14
Net Cash From Continuing Financing Activities		 59 3.09 27 0.25 0.33 0.07 -0.22 -0.16 0.68 140 0.14
Repayment of Debt		 - - - - - 0.00 - - - -1.31 -9.58
Issuance of Common Equity		 59 3.02 27 0.08 0.40 0.37 0.02 - 1.33 150 0.03
Other Financing Activities, net		 0.09 0.06 0.64 0.18 -0.08 -0.31 -0.24 -0.16 -0.21 -9.11 -0.31

Annual Balance Sheets for ALX Oncology

This table presents ALX Oncology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 11 436 380 306 243 148 59
Total Current Assets		 9.81 436 367 271 189 134 51
Cash & Equivalents		 9.02 434 364 49 22 18 16
Short-Term Investments		 - - 0.00 217 160 110 28
Prepaid Expenses		 0.26 1.77 3.35 4.76 5.92 6.60 5.94
Plant, Property, & Equipment, net		 0.86 0.05 0.90 3.89 3.59 2.91 1.20
Total Noncurrent Assets		 0.01 0.01 12 32 50 11 7.12
Long-Term Investments		 - - 0.00 17 35 3.52 3.49
Other Noncurrent Operating Assets		 0.01 0.01 12 15 15 6.99 3.63
Total Liabilities & Shareholders' Equity		 11 436 380 306 243 148 59
Total Liabilities		 11 6.21 17 43 53 34 33
Total Current Liabilities		 4.98 6.20 15 28 36 19 25
Short-Term Debt		 - - - - 0.00 0.44 5.22
Accounts Payable		 3.75 0.00 5.39 8.07 8.59 4.50 4.91
Accrued Expenses		 1.24 6.13 9.90 19 27 13 14
Other Current Liabilities		 - 0.07 - 1.65 0.54 0.15 0.00
Total Noncurrent Liabilities		 5.97 0.01 1.84 15 17 16 8.51
Long-Term Debt		 5.42 - 0.00 9.39 9.64 9.47 4.53
Other Noncurrent Operating Liabilities		 0.55 0.01 1.84 5.31 7.20 6.19 3.98
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -71 430 363 263 190 114 26
Total Preferred & Common Equity		 -71 430 363 263 190 114 26
Total Common Equity		 -71 430 363 263 190 114 26
Common Stock		 2.14 548 565 590 676 734 749
Retained Earnings		 -73 -119 -202 -325 -486 -621 -723
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 -0.85 0.26 0.28 0.03

Quarterly Balance Sheets for ALX Oncology

This table presents ALX Oncology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 220 213 215 186 121 95 83 178 161
Total Current Assets		 199 168 169 156 103 85 67 146 143
Cash & Equivalents		 20 14 16 16 21 19 23 32 23
Short-Term Investments		 170 143 141 132 77 60 37 108 116
Prepaid Expenses		 9.06 10 12 7.32 4.70 5.94 5.89 5.24 5.23
Plant, Property, & Equipment, net		 3.62 3.44 3.32 3.11 2.70 1.50 1.35 1.05 0.17
Total Noncurrent Assets		 17 41 43 27 16 8.57 15 32 17
Long-Term Investments		 6.44 27 29 14 9.16 4.23 5.84 29 15
Other Noncurrent Operating Assets		 11 14 13 13 6.50 4.33 9.02 2.93 2.05
Total Liabilities & Shareholders' Equity		 220 213 215 186 121 95 83 178 161
Total Liabilities		 51 48 55 49 33 31 38 27 25
Total Current Liabilities		 35 32 38 32 19 19 28 20 15
Short-Term Debt		 - - - - 1.74 3.04 4.35 5.22 0.00
Accounts Payable		 13 6.23 8.15 7.89 3.94 4.90 6.58 3.85 3.02
Accrued Expenses		 22 26 30 24 13 11 17 11 12
Other Current Liabilities		 0.27 0.38 0.23 0.06 0.05 0.04 0.00 0.00 0.00
Total Noncurrent Liabilities		 16 16 17 17 14 12 10 6.80 9.86
Long-Term Debt		 9.58 9.70 9.77 9.84 8.23 7.00 5.76 3.30 9.71
Other Noncurrent Operating Liabilities		 6.64 6.52 7.08 6.73 5.63 5.06 4.44 3.51 0.15
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 169 164 159 137 88 64 45 151 136
Total Preferred & Common Equity		 169 164 159 137 88 64 45 151 136
Total Common Equity		 169 164 159 137 88 64 45 151 136
Common Stock		 610 686 721 728 740 742 745 892 895
Retained Earnings		 -441 -522 -561 -592 -652 -678 -700 -741 -759
Accumulated Other Comprehensive Income / (Loss)		 -0.23 0.03 -0.07 0.56 0.12 0.04 0.04 -0.25 -0.22

Annual Metrics And Ratios for ALX Oncology

This table displays calculated financial ratios and metrics derived from ALX Oncology's official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 37,107,522.00 40,499,538.00 40,755,452.00 49,818,812.00 - 54,218,001.00
DEI Adjusted Shares Outstanding		 0.00 0.00 37,107,522.00 40,499,538.00 40,755,452.00 49,818,812.00 - 54,218,001.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -1.37 0.00 0.00 -3.23 - -1.88
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 132.03% -75.35% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -41.44% -136.71% -88.18% -53.29% -36.93% 16.71% 28.56%
EBIT Growth		 0.00% -40.20% -134.53% -85.69% -52.53% -33.29% 16.13% 26.97%
NOPAT Growth		 0.00% -40.19% -127.61% -91.36% -52.52% -33.62% 16.33% 26.99%
Net Income Growth		 0.00% -40.14% -137.70% -82.47% -47.95% -30.23% 16.14% 24.59%
EPS Growth		 0.00% -19.43% 0.00% 0.00% -46.38% -23.43% 31.02% 26.36%
Operating Cash Flow Growth		 0.00% -8.03% -168.71% -77.86% -31.02% -46.11% 6.48% 30.98%
Free Cash Flow Firm Growth		 0.00% 0.00% -214.59% -107.05% -28.16% -38.46% -0.28% 38.59%
Invested Capital Growth		 0.00% 0.00% -12.96% 85.87% -1,526.70% -86.97% 58.72% -61.80%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -13.24% -3.50% -10.67% 11.30% 7.18%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -13.15% -3.03% -10.28% 10.90% 6.79%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -14.60% -3.03% -10.23% 10.89% 6.80%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -13.10% -1.87% -10.11% 10.79% 5.85%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -1.34% -4.76% 13.13% 5.47%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -38.99% -6.03% -3.70% -17.07% 5.89% 13.44%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.78% -14.84% 2.89% 17.60%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -2,786.96% -63.12% -3.75% 51.41% -8.67%
Profitability Metrics		 - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -641.27% -390.91% -3,754.57% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -662.02% -399.98% -3,693.99% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -662.12% -400.08% -3,807.28% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -664.30% -401.23% -3,869.71% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.33% 100.18% 100.53% 99.97% 100.05% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.11% 101.10% 99.91% 96.83% 94.65% 94.64% 97.73%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 6,972.10% -21.30% -21.05% -39.42% -70.97% -88.91% -145.70%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -179.73% -20.15% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% -180.25% -20.48% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 1,784,428.53% -17.81% -21.05% -39.42% -70.97% -88.91% -145.70%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 27.24% -10.64% -22.99% -46.87% 0.00% -118.69% 0.00%
Net Operating Profit after Tax (NOPAT)		 -9.58 -13 -31 -58 -89 -119 -100 -73
NOPAT Margin		 -463.42% -279.99% -2,585.80% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -323.41% -6.93% -6.26% -10.76% -17.26% -21.29% -36.12%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -32.69% -59.79% -80.74% -203.79%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 125.83% 69.08% 1,252.88% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 545.23% 339.99% 2,450.17% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 762.02% 499.98% 3,793.99% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -14 -19 -45 -84 -127 -170 -142 -104
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -19 -44 -84 -128 -175 -146 -104
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 7.44 2.40 1.74 3.91 0.78 2.36
Price to Tangible Book Value (P/TBV)		 0.00 0.00 7.44 2.40 1.74 3.91 0.78 2.36
Price to Revenue (P/Rev)		 73.54 31.69 2,706.15 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 45.61 2,338.79 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 -19.64 0.00 0.00 0.04 0.05 0.09 0.38
Long-Term Debt to Equity		 0.00 -19.64 0.00 0.00 0.04 0.05 0.08 0.17
Financial Leverage		 0.00 13.03 -1.02 -1.01 -1.02 -1.06 -1.09 -1.15
Leverage Ratio		 0.00 -38.68 1.04 1.03 1.10 1.21 1.29 1.48
Compound Leverage Factor		 0.00 -38.72 1.05 1.03 1.06 1.15 1.22 1.45
Debt to Total Capital		 0.00% 105.36% 0.00% 0.00% 3.44% 4.84% 8.02% 27.29%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.35% 14.60%
Long-Term Debt to Total Capital		 0.00% 105.36% 0.00% 0.00% 3.44% 4.84% 7.67% 12.68%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 1,367.60% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -1,372.96% 100.00% 100.00% 96.56% 95.16% 91.98% 72.71%
Debt to EBITDA		 0.00 -0.29 0.00 0.00 -0.07 -0.06 -0.07 -0.09
Net Debt to EBITDA		 0.00 0.19 0.00 0.00 2.14 1.19 0.83 0.37
Long-Term Debt to EBITDA		 0.00 -0.29 0.00 0.00 -0.07 -0.06 -0.06 -0.04
Debt to NOPAT		 0.00 -0.40 0.00 0.00 -0.11 -0.08 -0.10 -0.13
Net Debt to NOPAT		 0.00 0.27 0.00 0.00 3.07 1.75 1.22 0.53
Long-Term Debt to NOPAT		 0.00 -0.40 0.00 0.00 -0.11 -0.08 -0.09 -0.06
Altman Z-Score		 0.00 -6.16 309.56 30.12 4.50 4.06 -6.58 -21.31
Noncontrolling Interest Sharing Ratio		 0.00% -25,493.84% 16.38% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 0.00 1.97 70.28 24.00 9.57 5.24 7.26 2.07
Quick Ratio		 0.00 1.92 69.99 23.78 9.40 5.08 6.91 1.82
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -9.56 -30 -62 -80 -110 -111 -68
Operating Cash Flow to CapEx		 -2,019.91% -4,036.54% 0.00% -10,225.38% -6,252.49% -10,232.65% -27,273.38% -39,689.62%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -48.41 -4,788.04 -335.17 -70.58 -64.06 -42.46
Operating Cash Flow to Interest Expense		 0.00 0.00 -61.66 -5,238.54 -374.89 -83.30 -70.51 -52.52
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -60.67 -5,289.77 -380.88 -84.11 -70.77 -52.66
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.45 0.01 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 8.95 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 5.58 2.59 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 40.79 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 40.79 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 0.00 -3.87 -4.37 -0.62 -10 -19 -7.76 -13
Invested Capital Turnover		 0.00 -2.48 -0.29 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -3.87 -0.50 3.76 -9.44 -8.74 11 -4.80
Enterprise Value (EV)		 0.00 219 2,764 507 186 533 -33 23
Market Capitalization		 152 152 3,199 870 459 742 88 61
Book Value per Share		 $0.00 ($22.96) $11.58 $8.96 $6.46 $3.81 $2.15 $0.48
Tangible Book Value per Share		 $0.00 ($22.96) $11.58 $8.96 $6.46 $3.81 $2.15 $0.48
Total Capital		 0.00 5.15 430 363 273 199 124 36
Total Debt		 0.00 5.42 0.00 0.00 9.39 9.64 9.90 9.75
Total Long-Term Debt		 0.00 5.42 0.00 0.00 9.39 9.64 9.47 4.53
Net Debt		 0.00 -3.60 -434 -364 -274 -209 -121 -39
Capital Expenditures (CapEx)		 0.65 0.35 -0.61 0.67 1.43 1.27 0.45 0.21
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -4.19 -4.43 -12 -24 -30 -11 -13
Debt-free Net Working Capital (DFNWC)		 0.00 4.83 430 352 243 153 116 31
Net Working Capital (NWC)		 0.00 4.83 430 352 243 153 116 26
Net Nonoperating Expense (NNE)		 4.15 5.81 15 25 34 42 35 29
Net Nonoperating Obligations (NNO)		 0.00 -3.60 -434 -364 -274 -209 -121 -39
Total Depreciation and Amortization (D&A)		 0.43 0.44 0.62 0.05 -0.55 -5.40 -3.52 -0.26
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -87.41% -374.87% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 100.60% 36,361.08% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 100.60% 36,361.08% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($2.07) $0.00 ($3.74) ($2.58) ($1.90)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 40.13M 40.63M 40.70M 42.99M 52.17M 53.66M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($2.07) $0.00 ($3.74) ($2.58) ($1.90)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 40.13M 40.63M 40.70M 42.99M 52.17M 53.66M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($2.07) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 18.49M 40.31M 40.86M 50.15M 53.38M 131.61M
Normalized Net Operating Profit after Tax (NOPAT)		 -9.58 -13 -31 -58 -89 -119 -100 -71
Normalized NOPAT Margin		 -463.42% -279.99% -2,585.80% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -662.12% -400.52% -3,849.32% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -72.47 -6,427.85 -535.54 -108.56 -82.41 -64.95
NOPAT to Interest Expense		 0.00 0.00 -49.22 -4,499.12 -374.81 -76.16 -57.68 -45.45
EBIT Less CapEx to Interest Expense		 0.00 0.00 -71.48 -6,479.08 -541.53 -109.37 -82.67 -65.09
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -48.24 -4,550.35 -380.81 -76.98 -57.94 -45.58
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.04% 0.00% -8.41% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for ALX Oncology

This table displays calculated financial ratios and metrics derived from ALX Oncology's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 49,818,812.00 50,152,082.00 52,100,107.00 52,671,790.00 - 53,384,145.00 53,444,020.00 53,551,134.00 54,218,001.00 131,608,278.00 134,562,917.00
DEI Adjusted Shares Outstanding		 49,818,812.00 50,152,082.00 52,100,107.00 52,671,790.00 - 53,384,145.00 53,444,020.00 53,551,134.00 54,218,001.00 131,608,278.00 134,562,917.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.91 -0.71 -0.76 -0.58 - -0.58 -0.49 -0.41 -0.42 -0.14 -0.13
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -51.61% -18.52% -12.50% 39.24% 37.44% 17.85% 37.27% 32.39% 25.97% 41.52% 30.79%
EBIT Growth		 -49.13% -17.65% -13.94% 38.88% 36.29% 15.74% 35.83% 30.79% 24.75% 41.01% 31.37%
NOPAT Growth		 -49.05% -17.26% -12.91% 38.87% 36.25% 15.74% 35.83% 30.81% 24.80% 40.40% 32.33%
Net Income Growth		 -48.07% -17.88% -15.34% 39.78% 35.87% 13.57% 34.14% 27.89% 21.65% 41.71% 30.74%
EPS Growth		 -22.67% 4.05% 9.52% 53.23% 42.39% 18.31% 35.53% 29.31% 20.75% 70.69% 73.47%
Operating Cash Flow Growth		 -91.98% -36.34% 16.22% 18.56% 19.23% 34.97% 11.89% 32.64% 40.77% 24.39% 31.40%
Free Cash Flow Firm Growth		 -89.61% -54.77% 54.63% 1.55% -30.53% -8.86% -87.39% 19.07% 65.13% 47.16% 46.65%
Invested Capital Growth		 -86.97% -67.37% -650.86% 11.86% 58.72% 17.59% 46.87% 27.66% -61.80% -5.98% 17.68%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 9.45% 21.37% -9.00% 21.71% 6.77% -3.25% 16.76% 15.61% -2.08% 18.44% 1.49%
EBIT Q/Q Growth		 9.81% 21.39% -9.95% 21.59% 5.99% -3.98% 16.28% 15.43% -2.22% 18.49% 2.60%
NOPAT Q/Q Growth		 9.86% 21.37% -9.97% 21.57% 6.00% -3.94% 16.25% 15.45% -2.17% 17.61% 4.92%
Net Income Q/Q Growth		 10.82% 21.75% -10.73% 22.06% 5.03% -5.46% 15.62% 14.66% -3.18% 21.54% -0.25%
EPS Q/Q Growth		 25.81% 22.83% -7.04% 23.68% 8.62% -9.43% 15.52% 16.33% -2.44% 59.52% 23.53%
Operating Cash Flow Q/Q Growth		 -27.34% 4.42% 29.95% 4.48% -26.28% 23.04% 5.10% 26.97% -11.04% 1.75% 13.89%
Free Cash Flow Firm Q/Q Growth		 1.84% 10.86% 35.80% -75.25% -30.15% 25.66% -10.52% 24.32% 43.93% -12.67% -11.57%
Invested Capital Q/Q Growth		 -3.75% 43.67% -61.62% 6.69% 51.41% -12.46% -4.18% -27.07% -8.67% 26.33% 19.07%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 94.63% 94.19% 94.86% 94.30% 95.26% 96.62% 97.37% 98.25% 99.18% 95.47% 98.26%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -70.97% -82.16% -92.17% -98.94% -88.91% -102.99% -104.21% -118.95% -145.70% -74.17% -80.65%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -70.97% -82.16% -92.17% -98.94% -88.91% -102.99% -104.21% -118.95% -145.70% -74.17% -80.65%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -101.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -34 -26 -29 -23 -21 -22 -19 -16 -16 -13 -13
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.92% -4.34% -5.28% -4.66% -4.69% -6.24% -5.84% -6.09% -8.42% -3.61% -4.92%
Return On Investment Capital (ROIC_SIMPLE)		 -16.86% -15.20% -17.19% -15.55% -17.35% -22.67% -25.05% -28.72% -45.10% -8.30% -8.65%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -48 -38 -42 -33 -31 -32 -27 -23 -23 -19 -18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -50 -39 -43 -33 -31 -32 -27 -23 -23 -19 -18
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.91 3.41 1.97 0.70 0.78 0.38 0.34 2.19 2.36 1.74 2.05
Price to Tangible Book Value (P/TBV)		 3.91 3.41 1.97 0.70 0.78 0.38 0.34 2.19 2.36 1.74 2.05
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 9.94 0.00 0.00 1.21 3.65 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 10.06% 0.00% 0.00% 82.39% 27.39% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.05 0.06 0.06 0.07 0.09 0.11 0.16 0.23 0.38 0.06 0.07
Long-Term Debt to Equity		 0.05 0.06 0.06 0.07 0.08 0.09 0.11 0.13 0.17 0.02 0.07
Financial Leverage		 -1.06 -1.04 -1.05 -1.11 -1.09 -1.08 -1.12 -1.15 -1.15 -1.08 -1.08
Leverage Ratio		 1.21 1.21 1.24 1.33 1.29 1.32 1.39 1.48 1.48 1.25 1.28
Compound Leverage Factor		 1.15 1.14 1.17 1.25 1.23 1.28 1.35 1.45 1.47 1.19 1.25
Debt to Total Capital		 4.84% 5.58% 5.78% 6.71% 8.02% 10.15% 13.48% 18.41% 27.29% 5.32% 6.65%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.35% 1.77% 4.09% 7.92% 14.60% 3.26% 0.00%
Long-Term Debt to Total Capital		 4.84% 5.58% 5.78% 6.71% 7.67% 8.38% 9.40% 10.50% 12.68% 2.06% 6.65%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 95.16% 94.42% 94.22% 93.29% 91.98% 89.85% 86.52% 81.59% 72.71% 94.68% 93.35%
Debt to EBITDA		 -0.06 -0.05 -0.05 -0.06 -0.07 -0.07 -0.08 -0.09 -0.09 -0.09 -0.12
Net Debt to EBITDA		 1.19 0.96 0.95 0.93 0.83 0.70 0.60 0.50 0.37 1.76 1.74
Long-Term Debt to EBITDA		 -0.06 -0.05 -0.05 -0.06 -0.06 -0.06 -0.06 -0.05 -0.04 -0.04 -0.12
Debt to NOPAT		 -0.08 -0.08 -0.08 -0.09 -0.10 -0.10 -0.12 -0.13 -0.13 -0.13 -0.17
Net Debt to NOPAT		 1.75 1.42 1.40 1.37 1.22 1.02 0.86 0.72 0.53 2.52 2.49
Long-Term Debt to NOPAT		 -0.08 -0.08 -0.08 -0.09 -0.09 -0.09 -0.08 -0.07 -0.06 -0.05 -0.17
Altman Z-Score		 5.72 3.67 -0.16 -3.07 -4.08 -6.97 -9.61 -10.63 -16.78 0.55 0.76
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.24 5.21 4.39 4.82 7.26 5.47 4.52 2.40 2.07 7.21 9.71
Quick Ratio		 5.08 4.89 4.08 4.59 6.91 5.22 4.21 2.19 1.82 6.95 9.36
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -25 -22 -14 -25 -32 -24 -27 -20 -11 -13 -14
Operating Cash Flow to CapEx		 -26,809.46% -25,624.32% -29,517.78% -17,030.87% -53,410.00% -41,105.00% -49,800.00% -30,523.21% -38,734.69% -37,296.00% -94,452.94%
Free Cash Flow to Firm to Interest Expense		 -59.94 -51.92 -33.18 -55.93 -76.03 -59.45 -65.86 -49.48 -29.56 -38.53 -11.97
Operating Cash Flow to Interest Expense		 -95.61 -88.82 -61.93 -56.90 -75.05 -60.75 -57.79 -41.89 -49.56 -56.34 -13.50
Operating Cash Flow Less CapEx to Interest Expense		 -95.97 -89.16 -62.14 -57.23 -75.19 -60.89 -57.91 -42.03 -49.68 -56.49 -13.52
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -19 -11 -17 -16 -7.76 -8.73 -9.09 -12 -13 -9.25 -7.48
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -8.74 -4.26 -15 2.15 11 1.86 8.02 4.42 -4.80 -0.52 1.61
Enterprise Value (EV)		 533 384 138 -57 -33 -64 -51 42 23 103 135
Market Capitalization		 742 559 314 96 88 33 22 98 61 264 279
Book Value per Share		 $3.81 $3.27 $3.06 $2.60 $2.15 $1.65 $1.21 $0.84 $0.48 $1.15 $1.01
Tangible Book Value per Share		 $3.81 $3.27 $3.06 $2.60 $2.15 $1.65 $1.21 $0.84 $0.48 $1.15 $1.01
Total Capital		 199 174 169 147 124 98 74 55 36 160 146
Total Debt		 9.64 9.70 9.77 9.84 9.90 9.97 10 10 9.75 8.51 9.71
Total Long-Term Debt		 9.64 9.70 9.77 9.84 9.47 8.23 7.00 5.76 4.53 3.30 9.71
Net Debt		 -209 -175 -176 -153 -121 -97 -74 -56 -39 -161 -144
Capital Expenditures (CapEx)		 0.15 0.15 0.09 0.15 0.06 0.06 0.05 0.06 0.05 0.05 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -30 -22 -26 -25 -11 -12 -9.86 -17 -13 -9.72 -9.55
Debt-free Net Working Capital (DFNWC)		 153 136 130 124 116 86 69 43 31 131 129
Net Working Capital (NWC)		 153 136 130 124 116 84 66 39 26 125 129
Net Nonoperating Expense (NNE)		 12 9.15 10 7.91 7.73 8.48 7.30 6.37 6.73 4.65 5.35
Net Nonoperating Obligations (NNO)		 -209 -175 -176 -153 -121 -97 -74 -56 -39 -161 -144
Total Depreciation and Amortization (D&A)		 -1.61 -1.28 -1.03 -0.76 -0.45 -0.25 -0.05 0.01 0.04 0.02 -0.19
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.92) ($0.71) ($0.76) ($0.58) ($0.53) ($0.58) ($0.49) ($0.41) ($0.42) ($0.17) ($0.13)
Adjusted Weighted Average Basic Shares Outstanding		 42.99M 50.12M 51.83M 52.69M 52.17M 53.36M 53.45M 53.58M 53.66M 104.57M 135.64M
Adjusted Diluted Earnings per Share		 ($0.92) ($0.71) ($0.76) ($0.58) ($0.53) ($0.58) ($0.49) ($0.41) ($0.42) ($0.17) ($0.13)
Adjusted Weighted Average Diluted Shares Outstanding		 42.99M 50.12M 51.83M 52.69M 52.17M 53.36M 53.45M 53.58M 53.66M 104.57M 135.64M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 50.15M 52.10M 52.67M 52.74M 53.38M 53.44M 53.55M 54.22M 131.61M 134.56M 138.28M
Normalized Net Operating Profit after Tax (NOPAT)		 -34 -26 -29 -23 -21 -22 -16 -16 -16 -13 -13
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -115.79 -88.47 -96.81 -73.01 -71.70 -78.40 -65.80 -55.24 -60.15 -56.73 -15.38
NOPAT to Interest Expense		 -81.00 -61.90 -67.76 -51.11 -50.19 -54.86 -46.06 -38.66 -42.07 -40.11 -10.62
EBIT Less CapEx to Interest Expense		 -116.14 -88.82 -97.02 -73.35 -71.84 -78.55 -65.92 -55.38 -60.28 -56.88 -15.40
NOPAT Less CapEx to Interest Expense		 -81.36 -62.25 -67.97 -51.45 -50.33 -55.01 -46.17 -38.80 -42.20 -40.26 -10.63
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

ALX Oncology remains a development-stage biotechnology company with no reported revenue across the periods provided. Its financial profile is therefore driven primarily by research spending, financing activity and investment income rather than operating sales.

Recent results show some improvement in spending and losses. Second-quarter 2026 operating expenses declined to $18.0 million from $19.0 million in the first quarter and $23.0 million in the fourth quarter of 2025. Research and development expense fell to $13.1 million from $13.6 million in Q1 2026 and $17.6 million in Q4 2025. The quarterly net loss narrowed to $18.0 million from $22.8 million in Q4 2025 and $25.9 million in Q2 2025.

  • Substantial liquidity: At June 30, 2026, ALX Oncology held $22.7 million in cash, $115.5 million in short-term investments and $15.1 million in long-term investments, for approximately $153.0 million of cash and investments.
  • Improving operating burn: Cash used in operating activities decreased to $16.1 million in Q2 2026 from $18.6 million in Q1, $19.0 million in Q4 2025 and $24.7 million in Q1 2024.
  • Narrower net losses: The Q2 2026 net loss of $18.0 million was the smallest quarterly loss in the provided period, compared with losses of $39.4 million in Q2 2024 and $50.0 million in Q3 2023.
  • Lower research spending: R&D expense has generally trended down from $34.7 million in Q2 2024 to $13.1 million in Q2 2026, which could extend the company’s cash runway if the reduction is sustainable.
  • Reduced debt burden: Total debt declined to $9.7 million at the end of Q2 2026, from $8.5 million in Q1 on a gross basis but from approximately $15.5 million in Q2 2025 and $15.3 million in Q2 2024. The company repaid $9.6 million of debt during Q2.
  • Strong short-term liquidity: Current assets of $143.5 million were nearly 10 times current liabilities of $14.8 million, indicating considerable capacity to meet near-term obligations.
  • Investment portfolio supports liquidity but is actively managed: Investment sales and maturities generated $12.3 million in Q2 2026, offsetting $5.8 million of purchases and producing $6.5 million of net investing cash flow. These proceeds are not recurring operating revenue.
  • Interest income remains meaningful: Interest and investment income was $1.5 million in Q2 2026, helping offset $1.2 million of interest expense, but this benefit depends on cash balances and market rates.
  • No revenue or gross profit: Revenue has remained at zero in every reported income statement supplied, leaving ALX Oncology dependent on cash reserves, investment income and external financing.
  • Continued dilution and accumulated losses: The company raised approximately $150.0 million through common equity issuance in Q1 2026, while weighted-average basic shares increased to 135.6 million in Q2 from 104.6 million in Q1. Retained earnings were negative $758.7 million at June 30, 2026, highlighting the cumulative cost of ongoing development.

The latest cash balance alone fell by $9.6 million during Q2, to $22.7 million, although the company increased short-term investments by $7.5 million. Including investments, the company appears to have several quarters of funding at the recent operating burn rate, but the runway will depend on clinical spending, trial results and whether additional equity financing is required.

Overall, the statements show improving expense control, lower quarterly losses and a well-capitalized balance sheet. However, ALX Oncology continues to generate no product revenue, consume cash from operations and rely on financing and asset maturities. Investors should monitor whether lower R&D spending reflects efficiency or a reduction in development activity, as well as the potential for further shareholder dilution.

11/13/26 11:43 AM ETAI Generated. May Contain Errors.

ALX Oncology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ALX Oncology's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

ALX Oncology's net income appears to be on a downward trend, with a most recent value of -$101.70 million in 2025, falling from -$13.73 million in 2018. The previous period was -$134.85 million in 2024. See where experts think ALX Oncology is headed by visiting ALX Oncology's forecast page.

ALX Oncology's total operating income in 2025 was -$104.02 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $104.02 million

Over the last 7 years, ALX Oncology's total revenue changed from $2.07 million in 2018 to $0.00 in 2025, a change of -100.0%.

In the past 11 quarters, ALX Oncology's cash and equivalents has ranged from $14.04 million in Q1 2024 to $32.28 million in Q1 2026, and is currently $22.69 million as of their latest financial filing in Q2 2026.

ALX Oncology had total debt of $9.75 million at the end of 2025, a 1.6% decrease from 2024, and none in 2018.

Over the last 7 years, ALX Oncology's book value per share changed from 0.00 in 2018 to 0.48 in 2025, a change of 47.9%.


Related Companies

Financial statements for NASDAQ:ALXO last updated on 8/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Trump compared today's market to 1929
President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...
USA Capital Gold | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...
Paradigm Press | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel